Sofinnova Targets Later Stage Firms With €275M Healthcare Crossover Fund

After four decades of exclusively backing early stage life science start-ups, French venture capitalist Sofinnova Partners has launched its first crossover fund to finance later stage private and small cap biotech and medtech companies.